ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2009
Detection and characterization of soluble CD93 released during inflammation.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 57 citations in OpenAlex.
- CD93 in Health and Disease: Bridging Physiological Functions and Clinical Applications.International journal of molecular sciences · 2025Review
- Administration of Purified Alpha-1 Antitrypsin in Salt-Loaded Hypertensive 129Sv Mice Attenuates the Expression of Inflammatory Associated Proteins in the Kidney.Biomolecules · 2025Article
- The interplay between hormonal vitamin D and lipopolysaccharide signaling on human neutrophil transcriptional responses.Frontiers in immunology · 2025Article
- Immuno-PET Imaging of CD93 Expression withMolecular pharmaceutics · 2024Article
- Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.Cancer cell international · 2023Review
- Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response.Engineering (Beijing, China) · 2023Article
- The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context.Frontiers in immunology · 2023Article
- Soluble CD93 lectin-like domain sequesters HMGB1 to ameliorate inflammatory diseases.Theranostics · 2023Article
- TheJournal of inflammation research · 2023Article
- CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance.Journal of molecular neuroscience : MN · 2022Article
- CD93 in macrophages: A novel target for atherosclerotic plaque imaging?Journal of cellular and molecular medicine · 2022Article
- Soluble Complement Component 1q Receptor 1 (sCD93) Is Associated with Graft Function in Kidney Transplant Recipients.Biomolecules · 2021Article
- Differential H4K16ac levels ensure a balance between quiescence and activation in hematopoietic stem cells.Science advances · 2021Article
- The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients.Scientific reports · 2021Article
- Genetic variance and plasma concentration of CD93 is associated with cardiovascular mortality: Results from a 6.7‑year follow‑up of a healthy community‑living elderly population.Molecular medicine reports · 2020Article
- Significance of Soluble CD93 in Type 2 Diabetes as a Biomarker for Diabetic Nephropathy: Integrated Results from Human and Rodent Studies.Journal of clinical medicine · 2020Article
- Radioimmunoimaging ofOncology letters · 2019Article
- CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA.Immunology · 2019Article
- C-type lectin family XIV members and angiogenesis.Oncology letters · 2019Review
- C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.The FEBS journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD93 is a cell surface glycoprotein that is required for efficient engulfment of apoptotic cells via an unknown mechanism. Recently, it was demonstrated that CD93 is proteolytically cleaved from the surface of activated human monocytes and neutrophils in response to inflammatory signals in vitro and that a soluble form of CD93 (sCD93) exists in human plasma.
objectiveThe objective of this study was to examine the relationship among production of sCD93, inflammation, and engulfment of apoptotic cells.
methodsSterile peritonitis was induced in C57BL/6 mice, and lavage fluid was analyzed for presence of sCD93 by ELISA and Western blot. Cellular infiltrate was assessed by flow cytometry and analyzed for its capacity to shed CD93 in vitro. Peritoneal lavage fluid (PLF) was examined for its ability to regulate engulfment of apoptotic cells.
resultsThere was an 8.9-fold increase in sCD93 following induction of peritonitis. Macrophages accounted for the majority of infiltrating leukocytes into the peritoneum when sCD93 levels were highest. Inflammatory peritoneal macrophages constitutively shed CD93 in vitro suggesting that this cell type contributes to elevated levels of sCD93 in vivo. Inflammatory PLF from wild-type mice containing elevated sCD93 significantly enhanced engulfment of apoptotic cells in vitro when compared to inflammatory fluid from CD93-deficient mice.
conclusionsThese data demonstrate that inflammation triggers release of sCD93 in vivo, identify the inflammatory macrophage as a source of sCD93, and provide insight into the mechanism by which CD93 contributes to engulfment of apoptotic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.